Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by:
ZymoGenetics Identifier:
First received: June 30, 2006
Last updated: September 4, 2008
Last verified: September 2008
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

Condition Intervention Phase
Lymphoma, Non-Hodgkin
Drug: recombinant human interleukin 21 and rituximab
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1, Open-Label, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered in Combination With Rituxan (Rituximab) in Subjects With B-Cell Non Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by ZymoGenetics:

Primary Outcome Measures:
  • Incidence and severity of adverse events through 1 month after completing treatment [ Time Frame: During treatment and through 1 month after completing treatment ]
  • Incidence and grade of clinical laboratory abnormalities through 1 month after treatment [ Time Frame: During treatment and through 1 month after completing treatment ]

Secondary Outcome Measures:
  • Disease response by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas 2 weeks after completion of the first treatment cycle [ Time Frame: Two and four weeks after completion of the first and second cycles, respectively ]
  • Immunogenicity by incidence of anti-rIL-21 antibodies up to 1 month after treatment [ Time Frame: During treatment and up to 1 month after completing treatment ]

Enrollment: 23
Study Start Date: June 2006
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: recombinant human interleukin 21 and rituximab
    rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
    Other Name: rituxan
Detailed Description:

This is a Phase 1 open-label dose-escalation study of rituximab + rIL-21 combination therapy, administered once weekly for 4 weeks following an initial treatment with one dose of rituximab alone to patients with B-cell non-Hodgkin's lymphoma (NHL) who have failed prior therapy(ies). A standard dose of rituximab will be used. Increasing doses of rIL-21 will be studied sequentially in different groups of patients, starting with 30 μg/kg.

Before starting treatment with rituximab + rIL-21, patients will be treated with one dose of rituximab alone to look for rituximab infusion-related symptoms (such as fever, chills, and rigors). Patients who have severe infusion-related side effects after the first dose of rituximab will not go on to receive IL-21. Those who do not have unacceptable rituximab-related side effects will receive intravenous rIL-21 at least 60 minutes after completing the rituximab infusion at the rest of the weekly dosing visits. Patients will be evaluated for safety over the course of the study. Disease evaluation (tumor restaging) will be performed 2 weeks following completion of the first 4-week treatment cycle. Patients with stable disease or better at this evaluation may go on to receive a second 4-week treatment cycle of rituximab + rIL-21. Patients may be in the study for 2 to 4 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of CD20+ B-cell NHL
  • Disease measurable by computed tomography (CT) scan
  • Has failed at least one prior systemic therapy for NHL
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hepatic and renal function
  • Adequate bone marrow function

Exclusion Criteria:

  • Presence of acute infection or other significant systemic illness
  • White blood cell (WBC) count > 50,000/mm3 in peripheral blood
  • Central nervous system involvement by malignancy
  • Previous allogenic transplant or autotransplant within 6 months of enrollment
  • Other current malignancy or known history of cancer within 5 years
  • Received systemic corticosteroids, chemotherapy, immunotherapy, biologic therapy, antibody therapy (e.g., rituximab), radiation therapy, and/or investigational agent(s) within 1 month of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00347971

United States, California
University of California, Los Angeles
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Study Director: Muriel Siadak, PA-C ZymoGenetics
  More Information

Responsible Party: Muriel Siadak, ZymoGenetics Identifier: NCT00347971     History of Changes
Other Study ID Numbers: 494E03
Study First Received: June 30, 2006
Last Updated: September 4, 2008

Keywords provided by ZymoGenetics:
Lymphoma, Non-Hodgkin

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on April 26, 2017